Acurx Pharmaceuticals (ACXP) stock jumped 218% after announcing a clinical trial for ibezapolstat, which showed 96% cure rate for C. difficile infection.
Announced data from cohort 4 of soquelitinib atopic dermatitis Phase 1 trial demonstrating positive safety and efficacy results, including in patients who have received prior systemic therapy ...
Announced data from cohort 4 of soquelitinib atopic dermatitis Phase 1 trial demonstrating positive safety and efficacy results, including in patients who have received prior systemic therapy Initiate ...
Positive data from EXPERTS-ALS could accelerate RT1999 towards a registration trial; RT1999 to be presented as a poster ...
Company’s anticipated pivotal clinical trial in Hypoplastic Left Heart Syndrome (HLHS) priced at the market under Nasdaq rules Private placement led by Coastlands Capital with participation from Janus ...
CoRegen's therapies are developed from the research by the late Dr. Bert O'Malley of Baylor College of Medicine. The ...
Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing ...
India Today on MSN
Govt tells parliament HPV vaccine rollout backed by strong safety system
Govt tells parliament HPV vaccine rollout backed by strong safety system ...
(Combat), a medical device company optimizing the delivery and efficacy of cancer therapeutics, today announced it has raised £2.6 million in the first close of a Series A financing to advance its ...
THE newly created Special Corruption High Court is expected to improve the handling of graft cases by tightening case ...
Clarity Pharmaceuticals (ASX: CU6) (Clarity or Company), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results